Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
irinotecan liposomal
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
CSPC Pharma
Drug class:
Topoisomerase I inhibitor
Related drugs:
‹
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
DS-1062a (11)
AZD8205 (5)
DS-7300 (5)
AMB302 (4)
BNT323 (4)
DB-1310 (4)
DM002 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
MK-2870 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
AZD5335 (1)
BAT8008 (1)
BL-M02D1 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
ESG401 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
SGN-35C (1)
SGN-CD30C (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
PRO1184 (1)
ABBV-706 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT324 (0)
BNT326 (0)
CEB-01 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GSK5733584 (0)
HA-irinotecan (0)
HLX43 (0)
HS-20093 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
JSKN003 (0)
LMP744 (0)
lentinan (0)
TLC388 (0)
M9140 (0)
MBK-103 (0)
MHB036C (0)
MHB088C (0)
MK-1200 (0)
NK012 (0)
etirinotecan pegol (0)
PRO1160 (0)
SHR-A1921 (0)
SHR-A2009 (0)
TQB2102 (0)
YL201 (0)
CBX-12 (0)
EP0057 (0)
LMP400 (0)
HR070803 (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
DS-6000 (0)
simmitecan (0)
topotecan episcleral (0)
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
DS-1062a (11)
AZD8205 (5)
DS-7300 (5)
AMB302 (4)
BNT323 (4)
DB-1310 (4)
DM002 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
nanoliposomal irinotecan (3)
PLX038 (3)
MK-2870 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
AZD5335 (1)
BAT8008 (1)
BL-M02D1 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
ESG401 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
SGN-35C (1)
SGN-CD30C (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
PRO1184 (1)
ABBV-706 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT324 (0)
BNT326 (0)
CEB-01 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GSK5733584 (0)
HA-irinotecan (0)
HLX43 (0)
HS-20093 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
JSKN003 (0)
LMP744 (0)
lentinan (0)
TLC388 (0)
M9140 (0)
MBK-103 (0)
MHB036C (0)
MHB088C (0)
MK-1200 (0)
NK012 (0)
etirinotecan pegol (0)
PRO1160 (0)
SHR-A1921 (0)
SHR-A2009 (0)
TQB2102 (0)
YL201 (0)
CBX-12 (0)
EP0057 (0)
LMP400 (0)
HR070803 (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
DS-6000 (0)
simmitecan (0)
topotecan episcleral (0)
›
Associations
News
Trials
Filter by
Latest
23d
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer (clinicaltrials.gov)
P=N/A, N=53, Recruiting, Kuirong Jiang
23 days ago
New trial
|
irinotecan liposomal
2ms
Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer (clinicaltrials.gov)
P=N/A, N=30, Recruiting, Tianjin Medical University Cancer Institute and Hospital
2 months ago
New trial
|
5-fluorouracil • leucovorin calcium • irinotecan liposomal
3ms
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov)
P1, N=78, Recruiting, Shanghai Zhongshan Hospital
3 months ago
New P1 trial • Metastases
|
UGT1A1*1*1
|
Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan liposomal
over2years
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P2, N=66, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd. | Trial completion date: Aug 2021 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
over 2 years ago
Clinical • Trial completion date • Trial primary completion date
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
UGT1A1*1*1
|
5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal
over2years
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
P2, N=153, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.
over 2 years ago
Clinical • New P2 trial
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
UGT1A1*1*1
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • irinotecan liposomal
over2years
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov)
P2, N=66, Not yet recruiting, CSPC Ouyi Pharmaceutical Co., Ltd.
over 2 years ago
Clinical • New P2 trial
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
UGT1A1*1*1
|
5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login